Broad Medicare Formularies Would Negatively Impact Rx Industry, PCMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Limiting PBMs’ ability to control costs in Medicare Rx would benefit advocates of a government-run health care system, Pharmaceutical Care Management Association CEO Merritt says. Broad drug formularies also would increase costs for employers, he says.